TrialEndocrine2018

Single and multiple ascending-dose study of glucagon-receptor antagonist RN909 in type 2 diabetes: a phase 1, randomized, double-blind, placebo-controlled trial.

Barry Gumbiner et al.PubMed ↗Publisher ↗

No numbers read from the abstract.